UP!

PDLI $2.47

PDLI target price
2.47
0
0
PDL BioPharma
Type
Public
Traded as NASDAQ: PDLI
Industry Biotechnology
Key people

John McLaughlin (CEO)
Peter Garcia (CFO)
Cary Queen (Founder, former vice-president in charge of research)

Lawrence J. Korn (Founder, former president)
Revenue $590.4 million (2015)
Website pdl.com

John McLaughlin (CEO)
Peter Garcia (CFO)
Cary Queen (Founder, former vice-president in charge of research)

PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.

Protein Design Labs had been founded in 1986 and was a pioneer in humanizing monoclonal antibodies. Its humanization technology was used in several monoclonal antibody drugs under licensing and collaboration agreements; such products included rituximab (Rituxan), bevacizumab (Avastin), and palivizumab (Synagis). It held its initial public offering in 1992 and by 1994 it had 13 compounds in its pipeline, and had partnered its lead product, the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty. Daclizumab became the first humanized monoclonal antibody approved for human use in 1997. PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001. In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year. These are the kinds of intellectual property and license agreements that PDL manages on behalf of its shareholders since 2008; in 2007 those royalty payments were around $220 million.

One of the development programs that PDL had transferred to Facet was the use of daclizumab in indications it had never licensed to Roche, including multiple sclerosis. Facet partnered that development program with Biogen Idec which attempted a hostile buy out of Facet for $350M in 2009; Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year. The FDA approved daclizumab for multiple sclerosis in 2016 under the trade name Zinbryta.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-11-11 -0.01 0.00
Q2 2020 2020-08-06 -0.43 -0.11
Q1 2020 2020-05-07 -0.26 -0.15
Q4 2019 2020-03-11 -0.48 -0.48
Q3 2019 2019-11-06 -0.16 -0.16
Q2 2019 2019-08-07 -0.04 -0.07
Q1 2019 2019-05-09 0.05 -0.07
Q4 2018 2019-03-14 0.11 0.12
Q3 2018 2018-11-06 0.18 0.18

Ratings

2016-04-17 Reiterated Rating Cowen and Company Hold
2016-02-23 Lower Price Target Cowen and Company Market Perform $5.50 to $4.00
2016-02-23 Lower Price Target RBC Capital Sector Perform $5.00 to $4.00
2016-02-23 Lower Price Target Royal Bank Of Canada Sector Perform $5.00 to $4.00
2016-02-22 Reiterated Rating Cowen and Company Hold
2016-02-02 Lower Price Target RBC Capital Sector Perform $6.00 to $5.00
2015-11-05 Lower Price Target RBC Capital Sector Perform $7.00 to $6.00
2015-10-16 Lower Price Target RBC Capital Sector Perform $8.00 to $7.00
2014-08-20 Boost Price Target Cowen and Company $7.00 to $8.00
2009-03-27 Upgrade Lazard Capital Mkts Hold to Buy $8
2009-03-03 Reiterated Wedbush Morgan Buy $15 to $9
2009-03-03 Reiterated JMP Securities Mkt Outperform $16 to $9
2009-01-05 Upgrade JP Morgan Underweight to Neutral
2008-12-10 Reiterated Credit Suisse Neutral $11 to $12
2008-09-11 Downgrade JP Morgan Neutral to Underweight
2008-06-13 Downgrade Credit Suisse Outperform to Neutral
2008-04-22 Downgrade Wachovia Outperform to Mkt Perform
2008-04-11 Reiterated Credit Suisse Outperform $19 to $16
2008-03-10 Downgrade Susquehanna Financial Positive to Neutral
2008-03-06 Reiterated BMO Capital Markets Market Perform $18 to $14
2008-03-05 Downgrade Broadpoint Capital Buy to Neutral
2008-02-05 Reiterated Lazard Capital Buy $25 to $21
2008-02-05 Reiterated BMO Capital Markets Market Perform $22 to $18
2008-01-10 Reiterated Lehman Brothers Overweight $26 to $21
1970-01-01
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-02-23 Lower Price Target Cowen and Company Market Perform $5.50 to $4.00
2016-02-23 Lower Price Target RBC Capital Sector Perform $5.00 to $4.00
2016-02-23 Lower Price Target Royal Bank Of Canada Sector Perform $5.00 to $4.00
2016-02-22 Reiterated Rating Cowen and Company Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
MCLAUGHLIN JOHN PETER 0.78%  (1252785) AAVL / PDLI / SGEN /
GARCIA PETER S Vice President, CFO 0.28%  (455024) BTX / MRNA / PDLI /
Stone Christopher Lewis VP and General Counsel 0.27%  (430787) PDLI /
SAXE JON S 0.26%  (421680) DRRX / PDLI / SCLN / VTGN /
Hart Danny J Jr. Assoc Genl Counsel/Asst Sec 0.24%  (387236) PDLI /
Monnet Dominique President 0.15%  (240200) PDLI /
SANDMAN PAUL W 0.13%  (208452) PDLI /
SELICK HAROLD E 0.13%  (202480) PDLI / PTGX / THLD / TRGT /
Lindell Jody S 0.13%  (201826) COO / PDLI /
GRYSKA DAVID W 0.10%  (165163) AERI / HPTX / INCY / PDLI / SGEN /
Edick Paul R 0.10%  (160215) DRTX / NEOS / NLNK / PDLI / SCMP /
Saks Samuel R 0.10%  (159842) ASPX / DEPO / PDLI / TNXP /
Pietzke Steffen Controller and CAO 0.09%  (139587) PDLI /
Hasnain Faheem President & CEO 0.08%  (125000) AMBI / PDLI / RCPT / VTL /
MURRAY RICHARD /CA/ EVP & CSO 0.04%  (70159) PDLI /
LARSON CHRISTINE R VP & Chief Financial Officer 0.04%  (62049) DVAX / PDLI /
FRANK FRED 0.02%  (33296) LNDC / PDLI /
Montez David Controller and CAO 0.02%  (26719) PDLI /
GAGE L PATRICK Interim CEO 0.01%  (19555) CYTK / PDLI / TTPH /
KLEIN JOSEPH III 0.01%  (16983) ISIS / PDLI /
Tomlinson Bruce Chief Financial Officer 0.01%  (16509) PDLI /
SHAH JAISIM SVP, Mktg & Bus. Affairs 0.01%  (16125) PDLI / SRNE /
McCamish Mark Anthony SVP & CMO 0.01%  (14924) PDLI /
GUGGENHIME ANDREW SVP & Chief Financial Officer 0.01%  (13255) DERM / PDLI /
WILSON KAREN J VP of Finance & PAO 0.01%  (10494) JAZZ / PDLI /
KRUMEL CAROLINE J Vice President of Finance 0.01%  (9384) PDLI /